UMIN ID: UMIN000001849
Registered date:04/04/2009
phase II study of Erlotinib for non-small cell lung cancer patients with EGFR mutation
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | non-small cell lung cancer |
| Date of first enrollment | 2008/06/01 |
| Target sample size | 35 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | erlotinib |
Outcome(s)
| Primary Outcome | response rate |
|---|---|
| Secondary Outcome | progression free survival, overall survival, toxicity |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Pericardial effusion With subjective symptoms. Superior vena cava syndrome with necessary of emergecy radiation. |
Related Information
| Primary Sponsor | Nagasaki Thoracic Oncology Group |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Nagasaki Thoracic Oncology Group |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Kohei Motoshima |
| Address | Japan |
| Telephone | |
| preiland5461@yahoo.co.jp | |
| Affiliation | Second department of Internal Medecine Nagasaki Thoracic Oncology Group |
| scientific contact | |
| Name | Yoichi Nakamura |
| Address | Sakamoto1-7-1,Nagasaki city Japan |
| Telephone | |
| Affiliation | Nagasaki University Hospital of Medecine Second department of Internal Medecine |